Pharmacotherapies for glaucoma

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Glaucoma is a group of progressive optic neuropathies in which the axons in the optic nerve are injured, retinal ganglion cell numbers are reduced and vision is gradually and permanently lost. The only approved and effective way to treat glaucoma is to reduce the intraocular pressure (IOP). This is usually accomplished by surgical and/or pharmacological means. Drugs designed to reduce IOP target one or more of the parameters that maintain it. These parameters (collectively known as aqueous humor dynamics) are the production rate of aqueous humor, the pressure in the episcleral veins and the drainage of aqueous humor through the trabecular or uveoscleral outflow pathways. Intraocular pressure lowering drugs can be classified as inflow or outflow drugs depending on whether they reduce aqueous humor inflow into the anterior chamber or improve aqueous humor outflow from the anterior chamber. Inflow drugs, like β adrenergic antagonists and carbonic anhydrase inhibitors, reduce the rate of aqueous humor production. Outflow drugs, like prostaglandin analogs, cholinergic agonists and sympathomimetics, increase the rate of drainage through the uveoscleral outflow pathway and/or increase the facility of outflow through the trabecular meshwork. Some drugs have mixed inflow/outflow effects. This review summarizes the pharmacological treatments for glaucoma in use today and some new drugs showing potential for use in the future.

Original languageEnglish (US)
Pages (from-to)824-840
Number of pages17
JournalCurrent Molecular Medicine
Volume10
Issue number9
DOIs
StatePublished - Dec 1 2010

Fingerprint

Drug therapy
Aqueous Humor
Glaucoma
Drug Therapy
Pharmaceutical Preparations
Intraocular Pressure
Anterior Chamber
Drainage
Optics
Pharmacology
Carbonic Anhydrase Inhibitors
Synthetic Prostaglandins
Trabecular Meshwork
Low Vision
Cholinergic Agonists
Optic Nerve Diseases
Sympathomimetics
Adrenergic Antagonists
Retinal Ganglion Cells
Optic Nerve

Keywords

  • Aqueous humor dynamics
  • Carbonic anhydrase inhibitors
  • Cholinergic agents
  • Glaucoma
  • Parasympathomimetics
  • Prostaglandins
  • Sympathomimetics

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology

Cite this

Pharmacotherapies for glaucoma. / Toris, Carol B.

In: Current Molecular Medicine, Vol. 10, No. 9, 01.12.2010, p. 824-840.

Research output: Contribution to journalArticle

Toris, Carol B. / Pharmacotherapies for glaucoma. In: Current Molecular Medicine. 2010 ; Vol. 10, No. 9. pp. 824-840.
@article{90ac16f31f3a4c8d91142b71286466a2,
title = "Pharmacotherapies for glaucoma",
abstract = "Glaucoma is a group of progressive optic neuropathies in which the axons in the optic nerve are injured, retinal ganglion cell numbers are reduced and vision is gradually and permanently lost. The only approved and effective way to treat glaucoma is to reduce the intraocular pressure (IOP). This is usually accomplished by surgical and/or pharmacological means. Drugs designed to reduce IOP target one or more of the parameters that maintain it. These parameters (collectively known as aqueous humor dynamics) are the production rate of aqueous humor, the pressure in the episcleral veins and the drainage of aqueous humor through the trabecular or uveoscleral outflow pathways. Intraocular pressure lowering drugs can be classified as inflow or outflow drugs depending on whether they reduce aqueous humor inflow into the anterior chamber or improve aqueous humor outflow from the anterior chamber. Inflow drugs, like β adrenergic antagonists and carbonic anhydrase inhibitors, reduce the rate of aqueous humor production. Outflow drugs, like prostaglandin analogs, cholinergic agonists and sympathomimetics, increase the rate of drainage through the uveoscleral outflow pathway and/or increase the facility of outflow through the trabecular meshwork. Some drugs have mixed inflow/outflow effects. This review summarizes the pharmacological treatments for glaucoma in use today and some new drugs showing potential for use in the future.",
keywords = "Aqueous humor dynamics, Carbonic anhydrase inhibitors, Cholinergic agents, Glaucoma, Parasympathomimetics, Prostaglandins, Sympathomimetics",
author = "Toris, {Carol B}",
year = "2010",
month = "12",
day = "1",
doi = "10.2174/156652410793937778",
language = "English (US)",
volume = "10",
pages = "824--840",
journal = "Current Molecular Medicine",
issn = "1566-5240",
publisher = "Bentham Science Publishers B.V.",
number = "9",

}

TY - JOUR

T1 - Pharmacotherapies for glaucoma

AU - Toris, Carol B

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Glaucoma is a group of progressive optic neuropathies in which the axons in the optic nerve are injured, retinal ganglion cell numbers are reduced and vision is gradually and permanently lost. The only approved and effective way to treat glaucoma is to reduce the intraocular pressure (IOP). This is usually accomplished by surgical and/or pharmacological means. Drugs designed to reduce IOP target one or more of the parameters that maintain it. These parameters (collectively known as aqueous humor dynamics) are the production rate of aqueous humor, the pressure in the episcleral veins and the drainage of aqueous humor through the trabecular or uveoscleral outflow pathways. Intraocular pressure lowering drugs can be classified as inflow or outflow drugs depending on whether they reduce aqueous humor inflow into the anterior chamber or improve aqueous humor outflow from the anterior chamber. Inflow drugs, like β adrenergic antagonists and carbonic anhydrase inhibitors, reduce the rate of aqueous humor production. Outflow drugs, like prostaglandin analogs, cholinergic agonists and sympathomimetics, increase the rate of drainage through the uveoscleral outflow pathway and/or increase the facility of outflow through the trabecular meshwork. Some drugs have mixed inflow/outflow effects. This review summarizes the pharmacological treatments for glaucoma in use today and some new drugs showing potential for use in the future.

AB - Glaucoma is a group of progressive optic neuropathies in which the axons in the optic nerve are injured, retinal ganglion cell numbers are reduced and vision is gradually and permanently lost. The only approved and effective way to treat glaucoma is to reduce the intraocular pressure (IOP). This is usually accomplished by surgical and/or pharmacological means. Drugs designed to reduce IOP target one or more of the parameters that maintain it. These parameters (collectively known as aqueous humor dynamics) are the production rate of aqueous humor, the pressure in the episcleral veins and the drainage of aqueous humor through the trabecular or uveoscleral outflow pathways. Intraocular pressure lowering drugs can be classified as inflow or outflow drugs depending on whether they reduce aqueous humor inflow into the anterior chamber or improve aqueous humor outflow from the anterior chamber. Inflow drugs, like β adrenergic antagonists and carbonic anhydrase inhibitors, reduce the rate of aqueous humor production. Outflow drugs, like prostaglandin analogs, cholinergic agonists and sympathomimetics, increase the rate of drainage through the uveoscleral outflow pathway and/or increase the facility of outflow through the trabecular meshwork. Some drugs have mixed inflow/outflow effects. This review summarizes the pharmacological treatments for glaucoma in use today and some new drugs showing potential for use in the future.

KW - Aqueous humor dynamics

KW - Carbonic anhydrase inhibitors

KW - Cholinergic agents

KW - Glaucoma

KW - Parasympathomimetics

KW - Prostaglandins

KW - Sympathomimetics

UR - http://www.scopus.com/inward/record.url?scp=78651313737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651313737&partnerID=8YFLogxK

U2 - 10.2174/156652410793937778

DO - 10.2174/156652410793937778

M3 - Article

C2 - 21091423

AN - SCOPUS:78651313737

VL - 10

SP - 824

EP - 840

JO - Current Molecular Medicine

JF - Current Molecular Medicine

SN - 1566-5240

IS - 9

ER -